EPROSARTAN (Eprosartan).

     2-Butil-1- (karboksibenzil parameters)? -2 - tenilimidazolakrilovaya acid.

     Synonym: Teveten, Teveten.

     Issued in the form maleata.

     Distinguished from other AT1- angiotenzinovyh receptor blockers (lozartana, irbesartana, kandesartana and telmisartana) high affinity to the above receptors, and blocking the influence not only on postisinapticheskie AT1- angiotenzinovye receptors in the peripheral vessels, but the presinapticheskie AT1- receptor neurons TSNS governing noradrenalina release.

     Quickly, but poorly absorbed in the digestive, bioavailability of approximately 13%, S-max 1-2 h; Being low in the liver biotransformation, mostly derived from export.

     Apply with arterial hypertension.

     For antigipertenzivnoy eprosartan effectiveness is comparable to amlodipine, nifedipinu ointment and exceeds lozartan, unlike non increases excretion of uric acid, so it can assign patients with nefrolitiazom.

     Apply inside from 0.6 g 1 every day, if necessary, in 2-3 weeks the daily dose increased to 0.8 g (for violations of the liver and kidneys, and in old age on 0,3-0,4 g in day).

     The main side effects: angionevrotichesky swelling, fatigue, headache, dizziness, weakness, diarrhoea, rarely cough.

     Contraindications: severe liver damage, pregnancy, breast-feeding.

     Form release: pills to 0.2; 0.3; 0.4 and 0.6 g (N. 14, 28).

Materials allowed to copy only with the active hyperlink to the handbook of medicines